All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Eli Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Rituximab biosimilar, rixathon, given ‘positive opinion’ by the EMA CHMP for use in Follicular and Diffuse Large B-Cell Lymphoma, and Chronic Lymphocytic Leukemia
On the 21st April 2017, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for granting marketing authorization for rixathon, a rituximab biosimilar monoclonal antibody targeting CD20 in B-cells.
The marketing approval application for rixathon was submitted by Sandoz GmbH. The CHMP concluded that rixathon shows “comparable quality, safety, and efficacy to Mabthera® (rituximab)” from Roche.
Rixathon will be available as a 500mg and as a 100mg concentrate for solution for infusion. The full indications for rixathon are listed below:
Non-Hodgkin Lymphoma (NHL)
- Rixathon is indicated for the treatment of previously untreated patients with stage III-IV FL in combination with chemotherapy
- Rixathon maintenance therapy is indicated for the treatment of FL patients responding to induction therapy
- Rixathon monotherapy is indicated for treatment of patients with stage III-IV FL who are chemo-resistant or are in their second or subsequent relapse after chemotherapy
- Rixathon is indicated for the treatment of patients with CD20 positive DLBCL in combination with CHOP chemotherapy.
Chronic Lymphocytic Leukemia (CLL)
- Rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and R/R CLL
- Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rixathon or patients’ refractory to previous rixathon plus chemotherapy
- Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rixathon or patients’ refractory to previous rixathon plus chemotherapy
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, what is the average vein-to-vein time when treating patients with DLBCL with a reimbursed CAR T-cell therapy (from apheresis to infusion)?